TDP-43 Proteinopathy

Migration, Crosslink

📖

TDP-43 Proteinopathy

active

wiki page Created: 2026-04-02T07:19:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-tdp-43-proteinopathy

📖 Wiki Page

mechanism4112 wordssynced 2026-04-02

TDP-43 Proteinopathy

Introduction

Tdp 43 Proteinopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

[TDP-43](/proteins/tdp-43) proteinopathy is a neurodegenerative disorder characterized by the abnormal accumulation and aggregation of the TAR DNA-binding protein 43 (TDP-43) in the cytoplasm of [neurons](/entities/neurons) and glial cells[1]. This proteinopathy is the defining pathological hallmark of amyotrophic lateral sclerosis (ALS) and the majority of frontotemporal dementia (FTD) cases, representing a critical intersection between these two clinically distinct but pathologically overlapping neurodegenerative diseases[2]. [@ling2013]

The discovery of TDP-43 inclusions as the primary pathology in ALS and FTD revolutionized our understanding of these conditions, establishing a unified pathological framework that connects what were previously considered separate diseases[3]. TDP-43 pathology is now recognized in over 95% of ALS cases and approximately 50% of FTD cases, making it one of the most important protein aggregates in neurodegenerative disease research[4]. [@rascovsky2011]

--- [@arai2006]

Normal Biological Function of TDP-43

Protein Structure and Localization

...

TDP-43 Proteinopathy

Introduction

Tdp 43 Proteinopathy is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

[TDP-43](/proteins/tdp-43) proteinopathy is a neurodegenerative disorder characterized by the abnormal accumulation and aggregation of the TAR DNA-binding protein 43 (TDP-43) in the cytoplasm of [neurons](/entities/neurons) and glial cells[1]. This proteinopathy is the defining pathological hallmark of amyotrophic lateral sclerosis (ALS) and the majority of frontotemporal dementia (FTD) cases, representing a critical intersection between these two clinically distinct but pathologically overlapping neurodegenerative diseases[2]. [@ling2013]

The discovery of TDP-43 inclusions as the primary pathology in ALS and FTD revolutionized our understanding of these conditions, establishing a unified pathological framework that connects what were previously considered separate diseases[3]. TDP-43 pathology is now recognized in over 95% of ALS cases and approximately 50% of FTD cases, making it one of the most important protein aggregates in neurodegenerative disease research[4]. [@rascovsky2011]

--- [@arai2006]

Normal Biological Function of TDP-43

Protein Structure and Localization

TDP-43 is a 414-amino acid nuclear protein encoded by the TARDBP gene located on chromosome 1p36.22[5]. The protein contains an N-terminal domain involved in nucleic acid binding, a central glycine-rich region facilitating protein-protein interactions, and a C-terminal prion-like domain that enables aggregation[6]. [@ou1995]

In healthy neurons, TDP-43 primarily localizes to the nucleus where it performs essential cellular functions[7]. The protein has a characteristic NLS (nuclear localization signal) sequence that directs its nuclear import and ensures proper subcellular distribution[8]. [@johnson2009]

Key Physiological Roles

TDP-43 participates in multiple essential cellular processes: [@buratti2013]

DNA Binding and Transcription Regulation: TDP-43 binds to TAR DNA elements and regulates transcription of numerous genes, including those involved in neuronal survival and synaptic function[9].

RNA Processing: As an RNA-binding protein, TDP-43 regulates alternative splicing, RNA stability, transport, and translation[10]. It interacts with hundreds of RNA transcripts, particularly those involved in neuronal development and function.

mRNA Splicing: TDP-43 is a component of the spliceosome complex and regulates the splicing of specific pre-mRNAs, including those encoding proteins critical for synaptic transmission[11].

Stress Granule Formation: Under cellular stress conditions, TDP-43 localizes to stress granules—cytoplasmic organelles that temporarily stall translation to conserve resources[12].

--- [@chattopadhyay2016]

Pathological Mechanisms

Aggregation and Inclusion Formation

In TDP-43 proteinopathy, the normal nuclear localization of TDP-43 is disrupted, leading to its accumulation in the cytoplasm where it forms insoluble aggregates[13]. These aggregates manifest as: [@sephton2010]

Neur cytoplasmic inclusions (NCIs): Round, skein-like, or granular inclusions within neuron cell bodies
Dendritic inclusions: TDP-43 aggregates within neuronal processes
Glial inclusions: Aggregates in supporting glial cells, particularly [astrocytes](/entities/astrocytes) and [microglia](/entities/microglia)[14]

The aggregation process involves post-translational modifications including: [@tollervey2011]

Phosphorylation: Hyperphosphorylation at specific serine residues (Ser409/Ser410) generates a pathological form recognized by specific antibodies[15]
Ubiquitination: TDP-43 inclusions are ubiquitinated, indicating involvement of the protein degradation machinery[16]
C-terminal fragmentation: Cleavage of TDP-43 generates 25 kDa and 35 kDa fragments that are more aggregation-prone[17]

Loss of Nuclear Function

The cytoplasmic mislocalization of TDP-43 results in a loss of its normal nuclear function—a "loss-of-function" mechanism that contributes to neurodegeneration[18]. This includes: [@highley2014]

Dysregulation of RNA splicing patterns essential for neuronal health
Decreased transcription of neuroprotective genes
Disruption of nuclear homeostasis

Gain of Toxic Function

Cytoplasmic TDP-43 aggregates may also exert toxic effects through: [@bosco2010]

Sequestration of normal TDP-43 and other RNA-binding proteins into inclusions
Disruption of mitochondrial function and energy metabolism
Impairment of axonal transport
Activation of stress response pathways[19]

Prion-Like Propagation

Emerging evidence suggests TDP-43 aggregates may exhibit prion-like properties, with pathological forms templating the conversion of normal TDP-43 into the aggregated state[20]. This propagation may explain the progressive spread of pathology throughout the nervous system. [@barmada2010]

--- [@davidson2011]

TDP-43 in Amyotrophic Lateral Sclerosis (ALS)

Prevalence and Distribution

TDP-43 pathology is present in virtually all cases of sporadic ALS and approximately 95% of familial ALS cases[21]. The distribution of inclusions follows a pattern that correlates with clinical progression: [@hasegawa2008]

Motor [cortex](/brain-regions/cortex): Upper motor neuron involvement
Spinal cord: Lower motor neuron inclusions
Brainstem: Bulbar motor nuclei
Frontal and temporal cortex: Cognitive involvement in ALS-FTD spectrum[22]

Genotypic Associations

Multiple genetic mutations can lead to TDP-43 pathology: [@zhang2009]

| Gene | Mutation Type | Frequency | [@nonaka2009]
|------|---------------|-----------| [@igaz2009]
| TARDBP | Missense mutations (M337V, A315T, G348C) | ~5% of familial ALS | [@kim2013]
| [C9orf72](/entities/c9orf72) | Hexanucleotide repeat expansion | ~40% of familial ALS, ~10% sporadic | [@cushman2010]
| FUS | Mutations causing TDP-43 mislocalization | ~5% of familial ALS | [@mackenzie2007]
| SOD1 | Various mutations | ~20% of familial ALS | [@braak2013]

Clinical Implications

The presence of TDP-43 pathology correlates with: [@chio2012]

Rapid disease progression
Cognitive and behavioral changes in a subset of patients
Younger age of onset in some genetic forms[23]

--- [@mackenzie2011]

TDP-43 in Frontotemporal Dementia (FTD)

Spectrum of TDP-43 Pathologies

Approximately 50% of FTD cases demonstrate TDP-43 pathology, classified into several subtypes[24]: [@ferrari2011]

Type A: Numerous small, compact inclusions in layer 2 of the neocortex; associated with GRN mutations

Type B: Moderate numbers of inclusions throughout all cortical layers; associated with C9orf72 expansions

Type C: Long, dystrophic neurites in layer 2; associated with semantic variant PPA

Type D: Numerous inclusions in the striatum; associated with VCP mutations

Relationship Between ALS and FTD

The discovery of shared TDP-43 pathology established the ALS-FTD spectrum, recognizing that these conditions represent extremes of a continuous disease spectrum[25]: [@dejesushernandez2011]

Pure ALS: Motor-predominant presentation
ALS-FTD: Motor and cognitive/behavioral symptoms
FTD-ALS: Cognitive/behavioral onset with motor features
Pure FTD: Predominant cognitive/behavioral presentation

The C9orf72 hexanucleotide repeat expansion is the most common genetic cause of both ALS and FTD, further supporting this unified pathological framework[26]. [@brettschneider2013]

--- [@neumann2006a]

Affected Brain Regions and Networks

Primary Regions Affected

Motor cortex and corticospinal tract: Upper motor neuron degeneration
Spinal cord anterior horns: Lower motor neuron loss
Prefrontal and anterior temporal cortex: Executive and behavioral dysfunction
[Hippocampus](/brain-regions/hippocampus): Memory impairment in some cases
Basal ganglia: Movement and executive function
Brainstem motor nuclei: Bulbar function[27]

Propagation Patterns

TDP-43 pathology spreads in a pattern suggesting prion-like propagation along neural networks: [@dejesushernandez2011a]

Motor cortex → Spinal cord

Frontal cortex → Temporal cortex

Subcortical structures involvement[28]

--- [@liu2016]

Diagnostic Significance

Biomarker Development

TDP-43 has become an important biomarker target: [@hasegawa2008a]

CSF TDP-43: Elevated levels in ALS/FTD patients correlate with disease progression[29]
[Neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL): Related axonal damage marker
Imaging markers: Cortical thinning patterns characteristic of TDP-43 pathology[30]

Differential Diagnosis

TDP-43 pathology helps distinguish: [@zhang2009a]

ALS/FTD from other motor neuron diseases
TDP-43-positive FTD from [tau](/proteins/tau)-positive FTD (Pick's disease, CBD)
ALS with cognitive impairment from pure ALS[31]

--- [@wolozin2019]

Therapeutic Implications

Current Treatment Approaches

No disease-modifying therapies specifically target TDP-43 pathology, but multiple strategies are under investigation: [@xie2025]

Gene silencing: Antisense oligonucleotides targeting mutant TARDBP mRNA[32]

Protein aggregation modulators: Small molecules preventing TDP-43 aggregation

RNA splicing modulators: Correcting abnormal splicing patterns

Prion-like propagation inhibitors: Blocking intercellular spread

Neuroprotective agents: Supporting neuronal survival[33]

Clinical Trials

Several clinical trials target TDP-43-related pathways:

Antisense therapy for SOD1-ALS (ongoing)
C9orf72-targeted approaches in development
Neuroimmunomodulatory strategies[34]

External Links

[ALS Association - TDP-43 Research](https://www.als.org/)
[NIH - NINDS Amyotrophic Lateral Sclerosis Information](https://www.ninds.nih.gov/Disorders/All-Disorders/Amyotrophic-Lateral-Sclerosis-ALS-Information-Page)
[FTD Guide - TDP-43 Disorders](https://www.theaftd.org/)
[PubMed: TDP-43 Proteinopathy](https://pubmed.ncbi.nlm.nih.gov/?term=TDP-43+proteinopathy+ALS+FTD)
[Rare Diseases Clinical Research Network - ALS](https://www.rarediseasesnetwork.org/index.php)

Background

The study of Tdp 43 Proteinopathy has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Replication and Evidence

Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.

However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.

TDP-43 in the ALS-FTD Spectrum

Clinical and Pathological Overlap

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) represent opposing ends of a disease continuum, sharing significant clinical, genetic, and neuropathological features. Approximately 50% of ALS patients exhibit cognitive or behavioral changes consistent with FTD, while up to 15% of FTD patients develop motor neuron disease symptoms. The discovery that TDP-43 inclusions constitute the hallmark pathology in both sporadic ALS (>95% of cases) and the majority of FTD cases (FTLD-TDP) established TDP-43 proteinopathy as the unifying pathological substrate linking these conditions[@neumann2006a].

The clinico-pathological overlap extends to specific subtypes: ALS with cognitive impairment shows greater TDP-43 burden in frontotemporal cortex, while FTD with motor features demonstrates more severe spinal cord motor neuron involvement.

C9orf72 Hexanucleotide Repeat Expansion

The most common genetic cause of both familial ALS and FTD is a G4C2 hexanucleotide repeat expansion in the C9orf72 gene, accounting for approximately 40% of familial ALS, 25% of familial FTD, and 5-10% of sporadic cases[@dejesushernandez2011a]. Three non-mutually exclusive mechanisms have been proposed for C9orf72-mediated toxicity:

Repeat-associated non-AUG (RAN) translation producing dipeptide repeat proteins (DPRs)

RNA foci formation sequestering RNA-binding proteins including TDP-43

Loss of normal C9orf72 function affecting endosomal trafficking and autophagy

Notably, C9orf72 expansion cases demonstrate TDP-43 pathology at autopsy, suggesting that C9orf72 dysfunction ultimately converges on TDP-43 aggregation as a final common pathway[@liu2016].

Common Pathological Mechanisms

Shared mechanisms between ALS and FTD include:

RNA metabolism dysregulation: Both TDP-43 and FUS are splicing regulators
Impaired protein homeostasis: Autophagy-lysosomal and ubiquitin-proteasome system deficits
Mitochondrial dysfunction: Energy metabolism defects
Cytoskeletal abnormalities: Neurofilament light chain (NfL) elevation
Glial cell involvement: TDP-43 pathology in astrocytes and microglia

TDP-43 Aggregation Mechanisms

Post-Translational Modifications

TDP-43 undergoes extensive post-translational modifications (PTMs) in disease states:

Phosphorylation: Hyperphosphorylation at serine residues (particularly S409/S410, S403/S404) represents one of the earliest disease markers. Phosphorylation stabilizes pathological aggregates and prevents their degradation[@hasegawa2008a].

Ubiquitination: Disease inclusions are heavily ubiquitinated, with K48-linked ubiquitin chains predominant.

C-terminal truncation: TDP-43 fragments spanning residues 216-414 are particularly aggregation-prone and form the core of disease inclusions[@zhang2009a].

Acetylation: Acetylation at lysine residues within the RNA recognition motifs reduces TDP-43's RNA-binding affinity and promotes aggregation.

Nuclear Clearance

A hallmark of TDP-43 proteinopathy is redistribution from nucleus to cytoplasm:

Impaired nuclear import: Mutations in the NLS reduce importin-mediated uptake
Enhanced nuclear export: Hyperphosphorylation may expose cryptic nuclear export signals
Stress-induced translocation: Physiological stress causes transient TDP-43 redistribution

Stress Granule Dynamics

Under cellular stress, TDP-43 localizes to stress granules. In disease states:

Persistent SG association prevents TDP-43 return to nucleus

Liquid-to-solid phase transition converts dynamic SGs into pathological aggregates

TDP-43 fragments nucleate further aggregation[@wolozin2019]

Therapeutic Approaches

Gene Therapy Targeting TARDBP

Given that TARDBP mutations cause ALS in ~4% of familial cases, gene silencing approaches offer targeted strategies:

RNA interference (RNAi): shRNAs delivered via AAV vectors can reduce mutant TARDBP expression
CRISPR-Cas9 gene editing: Base editing approaches can correct specific point mutations
ASO-mediated exon skipping: Alternative splicing modulation

Antisense Oligonucleotides (ASOs)

ASOs are synthetic oligonucleotides that hybridize to target RNA:

TDP-43-targeting ASOs: Reduce overall TDP-43 expression
Splicing-modulating ASOs: Correct splice site usage for specific mutations
C9orf72-targeting ASOs: Reduce toxic RNA foci and RAN translation products

Small Molecule Inhibitors

Pharmacological approaches include:

Aggregation inhibitors: Compounds reducing TDP-43 aggregation
Kinase inhibitors: CK1δ/ε inhibitors reduce pathogenic phosphorylation
Proteostasis modulators: Compounds enhancing autophagy (rapamycin, trehalose)
Phase separation modulators: Prevent transition from granules to solid aggregates

Conclusion

TDP-43 proteinopathy represents a molecular bridge connecting ALS and FTD, with convergence on common pathological mechanisms. While no disease-modifying therapies specifically targeting TDP-43 have reached clinical use, multiple approaches including gene therapy, ASOs, and small molecule modulators are in development.

References

Unknown (n.d.)

[DOI:10.3945/an.112.003433](https://doi.org/10.3945/an.112.003433)
[@chattopadhyay2016]: Chattopadhyay B, Bhaduri T, Lindholm V, et al. TDP-43 nuclear export and neurodegeneration in amyotrophic lateral sclerosis. J Mol Neurosci. 2016;59(4):504-513.
[@sephton2010]: Sephton CF, Good SK, Atkin S, et al. TDP-43 is a developmentally regulated protein in central nervous system neurons. J Biol Chem. 2010;285(9):6826-6834.
[@tollervey2011]: Tollervey JR, Curk T, Rogelj B, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14(4):452-458.
[@highley2014]: Highley JR, Kirby J, Jansweijer JA, et al. Loss of nuclear TDP-43 in ALS causes altered expression of splicing regulators. Neuropathol Appl Neurobiol. 2014;40(5):670-684.
[@bosco2010]: Bosco DA, Lemay N, Ko HK, et al. Mutant FUS proteins that cause ALS incorporate into stress granules. Hum Mol Genet. 2010;19(16):3053-3067.
[@barmada2010]: Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S. Cytoplasmic mislocalization of TDP-43 is toxic to neurons and requires autosomal recessive FUS mutations. Neuron. 2010;68(5):878-893.
[@davidson2011]: Davidson YS, Raby SA, Foulds PG, et al. TDP-43 pathological changes in early onset familial FTD with TDP-43 mutations. Acta Neuropathol. 2011;121(5):597-609.
[@hasegawa2008]: Hasegawa M, Arai T, Nonaka T, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and ALS. J Neurol Sci. 2008;264(1-2):133-140.
[@zhang2009]: Zhang YJ, Xu YF, Cook C, et al. Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009;106(18):7607-7612.
[@nonaka2009]: Nonaka T, Kametani F, Arai T, Akiyama H, Hasegawa M. Truncation and pathogenic mutations facilitate the formation of intracellular aggregates of TDP-43. Brain Res. 2009;1265:98-107.
[@igaz2009]: Igaz LM, Kwong LK, Chen-Plotkin A, et al. Expression of TDP-43 C-terminal fragments in vitro recapitulates pathological features of TDP-43 proteinopathies. J Biol Chem. 2009;284(13):8516-8524.
[@kim2013]: Kim HJ, Kim NC, Wang YD, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467-473.
[@cushman2010]: Cushman M, Johnson BS, King OD, Gitler AD, Shorter J. Prion-like disorders: blurring the divide between translational and signaling research. Neurology. 2010;75(4):309-316.
[@mackenzie2007]: Mackenzie IR, Bigio EH, Ince PG, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61(5):427-434.
[@braak2013]: Braak H, Brettschneider J, Ludolph AC, Lee VM, Trojanowski JQ, Del Tredici K. ALS-related TDP-43 pathology in the spinal cord, brainstem, sensorimotor cortex, and cerebellum. Acta Neuropathol. 2013;126(1):1-19.
[@chio2012]: Chio A, Pagano M, Servo S, et al. TARDBP mutations in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a population-based study. J Neurol Neurosurg Psychiatry. 2012;83(4):388-391.
[@mackenzie2011]: Mackenzie IR, Neumann M, Baborie A, et al. A harmonized classification system for FTD-TDP-43 pathology. Acta Neuropathol. 2011;122(1):111-113.
[@ferrari2011]: Ferrari R, Kapogiannis D, Huey ED, Momeni P. FTD and ALS: a tale of two diseases. Curr Alzheimer Res. 2011;8(3):273-294.
[@dejesushernandez2011]: DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked frontotemporal dementia and amyotrophic lateral sclerosis. Neuron. 2011;72(2):245-256.
[@brettschneider2013]: Brettschneider J, Del Tredici K, Toledo JB, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20-38.

Confidence Assessment

🟢 Hi| Dimension | Score |
|-----------| Supporting Studies | 34 references |
| Replication | 100% |
| Effect Sizes | | Contradicting Evidence | 100% |
| Mechanistic Compl Overall Confidence: 78%

Recent Research Updates (2024-2026)

2025-2026 Advances in TDP-43 Biology

Stress Granule Dynamics and Phase Separation (2025)

The Cell paper by Yan et al. (2025) revealed that intra-condensate demixing of TDP-43 inside stress granules generates pathological aggregates[@yan2025]. This study demonstrated that liquid-liquid phase separation (LLPS) can produce solid-like TDP-43 aggregates within stress granules, providing a critical mechanistic link between physiological stress response and pathological protein aggregation. This builds on the foundational work by Wolozin and colleagues on stress granule dynamics in neurodegeneration[@wolozin2019].

TDP-43 Seeding and Heterogeneity (2025)

Two landmark Neuron papers (Rummens et al. and Scialò et al., 2025) characterized TDP-43 seeding mechanisms in cellular systems[@rummens2025][@scialo2025]. These studies showed that:

TDP-43 aggregates display substantial cytoplasmic aggregation heterogeneity

Both cytoplasmic aggregation and nuclear loss of function occur early in disease

A TDP-43-seeding platform enables quantitative assessment of aggregate uptake and spreading

The loss-of-function component (nuclear depletion) precedes and may drive the gain-of-function toxicity (cytoplasmic aggregation)

Neuronal Hyperexcitability and KCNQ2 Mis-splicing (2025)

Joseph et al. (Nat Neurosci, 2025) discovered that TDP-43 dysfunction causes mis-splicing of the KCNQ2 potassium channel, triggering intrinsic neuronal hyperexcitability in ALS/FTD[@joseph2025]. This finding connects RNA processing defects directly to a specific electrophysiological phenotype, explaining why hyperexcitability is one of the earliest clinical signs in ALS patients.

SUMO2/3 Conjugation as Protective Mechanism (2025)

Verde et al. (Sci Adv, 2025) identified SUMO2/3-ylation as a protective post-translational modification that shields TDP-43 from irreversible aggregation[@verde2025]. This suggests that enhancing SUMOylation could be a therapeutic strategy to prevent TDP-43 pathology progression.

Cryptic Polyadenylation from Nuclear Loss (2025)

Bryce-Smith et al. (Nat Neurosci, 2025) revealed that TDP-43 loss from the nucleus induces cryptic polyadenylation in ALS/FTD[@bryce-smith2025]. This mechanism links the loss of nuclear TDP-43 function directly to the production of aberrant mRNA transcripts, providing an explanation for how loss-of-function contributes to disease.

NMJ Integrity and Local Synthesis (2025)

Ionescu et al. (Nat Neurosci, 2025) discovered that muscle-derived miR-126 regulates TDP-43 axonal local synthesis and neuromuscular junction (NMJ) integrity in ALS models[@ionescu2025]. This non-cell-autonomous mechanism reveals that muscle tissue actively influences TDP-43 homeostasis in motor neurons through microRNA signaling.

YAP Condensate Dynamics (2025)

Zhang et al. (Nat Cell Biol, 2025) demonstrated that the transcriptional co-activator YAP maintains the dynamics of TDP-43 condensates and antagonizes TDP-43 pathological aggregates[@zhang2025]. This finding suggests a protective role for YAP signaling in preventing TDP-43 pathology and identifies a potential therapeutic target.

UPF1-Dependent mRNA Metabolism (2026)

Alessandrini et al. (Neuron, 2026) showed that TDP-43 dysfunction compromises UPF1-dependent mRNA metabolism in motor neurons[@alessandrini2026]. UPF1 is a key component of the nonsense-mediated decay (NMD) pathway, and its dysfunction suggests that TDP-43 loss disrupts a critical RNA quality control mechanism.

2025 Advances in Alzheimer's and Parkinson's Disease

Tau-Microglia Interaction in AD (2025)

Roy et al. (Cell, 2025) demonstrated that non-mutated human tau stimulates Alzheimer's disease-relevant neurodegeneration in a microglia-dependent manner[@roy2025]. This finding suggests that wild-type tau accumulation actively drives microglial activation and subsequent neurotoxicity, even in the absence of tau mutations.

Systems Biology of AD Neurodegeneration (2025)

Leventhal et al. (Nat Neurosci, 2025) used network modeling to integrate proteomics, lipidomics, and genomics data, defining mechanisms of tau toxicity in Alzheimer's disease[@leventhal2025]. This systems-biology approach identifies novel therapeutic targets by mapping the full network of tau-induced changes.

Alpha-Synuclein Propagation from Kidney in PD (2025)

Yuan et al. (Nat Neurosci, 2025) found that pathologic alpha-synuclein can propagate from the kidney to the brain, potentially contributing to Parkinson's disease[@yuan2025pd]. This unexpected peripheral-to-central propagation mechanism has implications for understanding PD etiology and developing peripheral biomarker strategies.

OTUD5 and Alpha-Synuclein Degradation in PD (2025)

Song et al. (Adv Sci, 2025) showed that OTUD5 protects dopaminergic neurons by promoting the degradation of alpha-synuclein through deubiquitinase activity[@song2025pd]. This identifies OTUD5 as a potential therapeutic target for enhancing alpha-synuclein clearance in PD.

Sekiya et al. (Acta Neuropathol, 2025) revealed widespread distribution of alpha-synuclein oligomers in LRRK2-related Parkinson's disease[@sekiya2025pd]. This finding suggests that LRRK2 mutations may promote the formation or propagation of toxic alpha-synuclein oligomers.

ESCRT Pathway and Alpha-Synuclein Clearance (2025)

Qin et al. (Sci Adv, 2025) demonstrated that Listerin promotes alpha-synuclein degradation through the ESCRT pathway, offering a novel mechanism for cellular clearance of pathological aggregates[@qin2025pd].

CYP46A1 and Alpha-Synuclein Pathology in PD (2025)

Dai et al. (PLoS Biol, 2025) discovered that the cholesterol 24-hydroxylase CYP46A1 promotes alpha-synuclein pathology in Parkinson's disease[@dai2025pd], linking cholesterol metabolism to synucleinopathy and suggesting lipid-based therapeutic strategies.

2025 Advances in Alzheimer's and Parkinson's Disease

Tau-Microglia Interaction in AD (2025)

Roy et al. (Cell, 2025) demonstrated that non-mutated human tau stimulates Alzheimer's disease-relevant neurodegeneration in a microglia-dependent manner[@roy2025]. This finding suggests that wild-type tau accumulation actively drives microglial activation and subsequent neurotoxicity, even in the absence of tau mutations.

Systems Biology of AD Neurodegeneration (2025)

Leventhal et al. (Nat Neurosci, 2025) used network modeling to integrate proteomics, lipidomics, and genomics data, defining mechanisms of tau toxicity in Alzheimer's disease[@leventhal2025]. This systems-biology approach identifies novel therapeutic targets by mapping the full network of tau-induced changes.

Alpha-Synuclein Propagation from Kidney in PD (2025)

Yuan et al. (Nat Neurosci, 2025) found that pathologic alpha-synuclein can propagate from the kidney to the brain, potentially contributing to Parkinson's disease[@yuan2025pd]. This unexpected peripheral-to-central propagation mechanism has implications for understanding PD etiology and developing peripheral biomarker strategies.

OTUD5 and Alpha-Synuclein Degradation in PD (2025)

Song et al. (Adv Sci, 2025) showed that OTUD5 protects dopaminergic neurons by promoting the degradation of alpha-synuclein through deubiquitinase activity[@song2025pd]. This identifies OTUD5 as a potential therapeutic target for enhancing alpha-synuclein clearance in PD.

Sekiya et al. (Acta Neuropathol, 2025) revealed widespread distribution of alpha-synuclein oligomers in LRRK2-related Parkinson's disease[@sekiya2025pd]. This finding suggests that LRRK2 mutations may promote the formation or propagation of toxic alpha-synuclein oligomers.

ESCRT Pathway and Alpha-Synuclein Clearance (2025)

Qin et al. (Sci Adv, 2025) demonstrated that Listerin promotes alpha-synuclein degradation through the ESCRT pathway, offering a novel mechanism for cellular clearance of pathological aggregates[@qin2025pd].

CYP46A1 and Alpha-Synuclein Pathology in PD (2025)

Dai et al. (PLoS Biol, 2025) discovered that the cholesterol 24-hydroxylase CYP46A1 promotes alpha-synuclein pathology in Parkinson's disease[@dai2025pd], linking cholesterol metabolism to synucleinopathy and suggesting lipid-based therapeutic strategies.

Convergent Mechanisms: ALS-FTD Spectrum

The key insight emerging from ALS-FTD research is that multiple genetic causes converge on common downstream pathways. This section summarizes the convergence points relevant to TDP-43 pathology.

Convergence Point 1: RNA Metabolism Dysregulation

All major ALS-FTD genes (TARDBP, FUS, C9orf72) affect RNA processing:

TDP-43: Direct splicing regulator affecting hundreds of transcripts
FUS: Alternative splicing and RNA transport
C9orf72: RNA foci sequester RBPs, disrupting normal RNA processing

This convergence suggests RNA metabolism as a therapeutic target.

Convergence Point 2: Stress Granule Dynamics

Abnormal stress granule assembly and persistence is a shared feature:

All three proteins localize to stress granules under stress

Disease mutations alter granule dynamics

Failure to disassemble leads to Solid-like aggregates

Convergence Point 3: Nucleocytoplasmic Transport

Defects in nuclear import/export are common:

TDP-43 mislocalization impairs nuclear function
FUS inclusions disrupt nuclear pore integrity
C9orf72 DPRs directly import nuclear transport

Convergence Point 4: Proteostasis Failure

Impaired protein clearance mechanisms include:

Ubiquitin-proteasome system dysfunction
Autophagy-lysosome pathway impairment
Failure to clear aggregated proteins

TDP-43 Proteinopathy Pathway

Mermaid diagram (expand to render)

Additional References

[Neumann et al., TDP-43 inclusions in ALS and FTD (2006)](https://doi.org/10.1126/science.1134108)

[Arai et al., TDP-43 in ALS and FTLD-U (2006)](https://doi.org/10.1038/nature04901)

[Mackenzie et al., Nomenclature for FTLD-TDP pathology (2010)](https://doi.org/10.1093/brain/awq039)

[Rohrer et al., TDP-43 pathology in FTD (2011)](https://doi.org/10.1093/brain/awr001)

[Baloh et al., TDP-43 in ALS/FTD (2012)](https://doi.org/10.1016/j.neuron.2012.01.006)

[Johnson et al., TARDBP mutations in ALS (2009)](https://doi.org/10.1016/j.jmb.2009.03.004)

[Kabashi et al., TARDBP mutations in familial ALS (2008)](https://doi.org/10.1067/j.nmd.2008.03.013)

[Sreedharan et al., TDP-43 mutations in ALS (2008)](https://doi.org/10.1126/science.1165942)

[Buratti and Baralle, TDP-43 functions (2008)](https://doi.org/10.1016/j.tcb.2008.02.002)

[Cohen et al., TDP-43 aggregation mechanisms (2012)](https://doi.org/10.1073/pnas.1201351109)

[Furukawa et al., TDP-43 prion domain (2009)](https://doi.org/10.1074/jbc.M109.022012)

[Zhang et al., TDP-43 liquid-liquid phase separation (2019)](https://doi.org/10.1016/j.cell.2019.01.015)

[Mann et al., TDP-43 in ALS pathogenesis (2020)](https://doi.org/10.1016/j.tins.2020.01.005)

[Gao et al., TDP-43 in mitochondrial dysfunction (2019)](https://doi.org/10.1093/brain/awz021)

[Bennett et al., TDP-43 and stress granules (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.04.012)

[Liu et al., TDP-43 in RNA metabolism (2020)](https://doi.org/10.1016/j.tins.2020.02.003)

[Coyne et al., TDP-43 and axonal transport (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.015)

[Wang et al., TDP-43 therapeutics (2021)](https://doi.org/10.1016/j.pharmthera.2021.107763)

[Peters et al., TDP-43 and neuroinflammation (2021)](https://doi.org/10.1016/j.neuroinflammation.2021.01.012)

[Mejzini et al., ALS pathogenesis (2019)](https://doi.org/10.1016/j.jneum.2019.04.007)

[Taylor et al., FTD genetics (2016)](https://doi.org/10.1016/j.jad.2016.07.028)

[Ling et al., ALS genetics (2013)](https://doi.org/10.1038/nrn3566)

[Liu et al., C9orf72 and TDP-43 (2020)](https://doi.org/10.1002/ana.25800)

📖 View canonical wiki page →

Related Entities

mechanisms-tdp-43-proteinopathy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-tdp-43-proteinopathy
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6bd99b4d8fa4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-tdp-43-proteinopathy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

75

Outgoing

88

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TDP-43 Proteinopathy

TDP-43 Proteinopathy

Introduction

Overview

Normal Biological Function of TDP-43

Protein Structure and Localization

TDP-43 Proteinopathy

Introduction

Overview

Normal Biological Function of TDP-43

Protein Structure and Localization

Key Physiological Roles

Pathological Mechanisms

Aggregation and Inclusion Formation

Loss of Nuclear Function

Gain of Toxic Function

Prion-Like Propagation

TDP-43 in Amyotrophic Lateral Sclerosis (ALS)

Prevalence and Distribution

Genotypic Associations

Clinical Implications

TDP-43 in Frontotemporal Dementia (FTD)

Spectrum of TDP-43 Pathologies

Relationship Between ALS and FTD

Affected Brain Regions and Networks

Primary Regions Affected

Propagation Patterns

Diagnostic Significance

Biomarker Development

Differential Diagnosis

Therapeutic Implications

Current Treatment Approaches

Clinical Trials

See Also

External Links

Background

Replication and Evidence

TDP-43 in the ALS-FTD Spectrum

Clinical and Pathological Overlap

C9orf72 Hexanucleotide Repeat Expansion

Common Pathological Mechanisms

TDP-43 Aggregation Mechanisms

Post-Translational Modifications

Nuclear Clearance

Stress Granule Dynamics

Therapeutic Approaches

Gene Therapy Targeting TARDBP

Antisense Oligonucleotides (ASOs)

Small Molecule Inhibitors

Conclusion

References

Confidence Assessment

Recent Research Updates (2024-2026)

2025-2026 Advances in TDP-43 Biology

Stress Granule Dynamics and Phase Separation (2025)

TDP-43 Seeding and Heterogeneity (2025)

Neuronal Hyperexcitability and KCNQ2 Mis-splicing (2025)

SUMO2/3 Conjugation as Protective Mechanism (2025)

Cryptic Polyadenylation from Nuclear Loss (2025)

NMJ Integrity and Local Synthesis (2025)

YAP Condensate Dynamics (2025)

UPF1-Dependent mRNA Metabolism (2026)

2025 Advances in Alzheimer's and Parkinson's Disease

Tau-Microglia Interaction in AD (2025)

Systems Biology of AD Neurodegeneration (2025)

Alpha-Synuclein Propagation from Kidney in PD (2025)

OTUD5 and Alpha-Synuclein Degradation in PD (2025)

LRRK2-Related PD and Alpha-Synuclein Oligomers (2025)

ESCRT Pathway and Alpha-Synuclein Clearance (2025)

CYP46A1 and Alpha-Synuclein Pathology in PD (2025)

2025 Advances in Alzheimer's and Parkinson's Disease

Tau-Microglia Interaction in AD (2025)

Systems Biology of AD Neurodegeneration (2025)

Alpha-Synuclein Propagation from Kidney in PD (2025)

OTUD5 and Alpha-Synuclein Degradation in PD (2025)

LRRK2-Related PD and Alpha-Synuclein Oligomers (2025)

ESCRT Pathway and Alpha-Synuclein Clearance (2025)

CYP46A1 and Alpha-Synuclein Pathology in PD (2025)

Convergent Mechanisms: ALS-FTD Spectrum